IOLCP's stock rallies 10% after securing nod for cholesterol drug

The stock price jump came after the company got China's drug regulatory authority NMPA's nod for cholesterol drug Fenofibrate, allowing the company to export it to the Chinese market

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing
SI Reporter New Delhi
2 min read Last Updated : Jul 02 2024 | 11:04 AM IST
Shares of IOL Chemicals and Pharmaceuticals (IOLCP) rallied 9.7 per cent at Rs 449 per share on the BSE in Tuesday’s intraday trade. The stock price jump came after the company got China's drug regulatory authority NMPA's nod for cholesterol drug Fenofibrate, allowing the company to export it to the Chinese market. 

Fenofibrate is used in the treatment of high cholesterol and triglyceride levels in the blood.

“We wish to inform you that the China’s Drug Regulatory Authority viz National Medical Products Administration (NMPA), China has approved the product “Fenofibrate” manufactured by the Company. This will enable the Company to export its Fenofibrate API in the China market,” the company said in an exchange filing. 

The company specialises in the manufacturing and sale of pharmaceutical and chemical products.

In the fourth quarter of fiscal year 2023-24, the company saw a 2.8 per cent year on year growth in total sales at Rs 573 crore. The company’s profit after tax surged by 135 per cent to Rs 65 crore in Q4FY24 from Rs 37 crore in the year ago period. 

The small company has total market cap of 2,547 crore and is presently trading at a price to earnings multiple of 17.74 with an earning per share of Rs 23.07.  

The stock price of the company has zoomed 36.4 per cent in the last one month, while rallying by 69.5 per cent in the last one year. 

At 10:55 AM; the stock of the company was trading 6 per cent higher at Rs 434 per share on the BSE. In comparison, the BSE Sensex was down marginally by 0.02 per cent at 79,493 levels. 

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Buzzing stocksMarkets Sensex NiftyBSE NSEStocks in focusIOL Chemicals and Pharmaceuticals

First Published: Jul 02 2024 | 11:04 AM IST

Next Story